Why Is REPLIMUNE GROUP INC (REPL) Stock Up Today?

Replimune Group shares surged 23.07% to close at $16.06, marking a new 52-week high. The primary driver was the company’s fiscal second quarter 2027 earnings report, which showed a GAAP EPS of negative $0.54, beating the consensus estimate of negative $0.77 by $0.21.

What Happened

Replimune announced the commercial availability of TUDRIQEV in the United States for the treatment of unresectable advanced cutaneous melanoma. The product launched with a price tag of $450,000 and has seen early adoption across oncology institutions. The company reported that its cash position rose to $307.8 million while research and development costs decreased. Management indicated an expectation to secure a permanent J-code by April 2027. Jefferies raised its price target for the stock to $29 from $24 following the results.

What The Data Shows

The stock printed 43 fresh 52-week highs and six fresh 52-week lows on October 28, 2026. The 52-week range spans from $1.50 to $16.33, with the current price sitting near the upper bound of that interval. Over the last eight sessions prior to the surge, the stock had moved down 0.5%, declining from $13.10 to $13.04. The company has a market capitalization of $1.2 billion and remains unprofitable with a trailing twelve-month EPS of negative $3.15. Its beta is 0.94. In the last 90 days, insider filings recorded zero buys and five sells totaling $1.0 million, with the most recent transaction on August 19, 2026. Specific recent sales include transactions by CEO Sushil Patel and CFO Emily Luisa Hill in August 2026.

What To Watch

Investors will monitor the company’s progress toward securing a permanent J-code by April 2027 and the alignment of payer coverage for TUDRIQEV. These factors are critical to determining whether early traction translates into sustained revenue growth for the firm.